Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test to rule out Alzheimer’s associated amyloid pathology.The minimally…
CAMBRIDGE, Mass., June 25, 2025 /PRNewswire/ -- A new survey report by MIT Technology Review Insights reveals the best practices for…
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage…
After a thorough clinical review, the benefit-risk for the use of Elevidys in non-ambulatory patients with Duchenne has been re-assessed,…
JUPITER, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- In a milestone rarely achieved in the clinical laboratory industry, Access Medical…
Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with SMA Evrysdi offers…
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an…
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced…